What makes a great year for takeovers?
The number of biopharma buyouts overall last year did not rise, though more deals were struck in the “sweet spot”, and premiums saw a healthy rise.
A big finish confirms 2019 as a takeover year to remember
Two megamergers meant that 2019 was always going to be a big year for biopharma M&A in dollar terms – and then came a late flurry of deals.
Vantage 2020 Preview – what’s in store for the biopharma sector?
Available to download for free now, our annual preview takes a data-driven look at 2020. Uncover biopharma’s biggest growth drivers, and see where the money is flowing.
Ash 2019 winners and losers
Data and M&A lifts buoyant biopharma companies from Fate Therapeutics to Rocket, though on share price gain Forty Seven wins Ash 2019.
Sanofi’s new broom cleans house
Paul Hudson has laid out his vision for Sanofi and it does not include diabetes or me-too products.
Sanofi goes all in with $2.5bn Synthorx buy
The French drugmaker bets big as it plays catch-up in the immuno-oncology space with a next-generation IL-2 buyout.
Upcoming events – Kalvista aims for acuity and a me-too from Sanofi approaches
As Kalvista hopes to attract Merck & Co, Sanofi plays catch-up with Genmab.
Novartis bets $9.7bn on RNA interference
The Swiss group does another deal to access a novel technology, taking out the RNAi specialist The Medicines Company.
AHA 2019 – The Medicines Company reaches for the stars
Two more Orion trials have hit neatly and cleanly, and now success will be largely down to pricing.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.